What is Sustanon 300?
Sustanon 300 is a ready-made oil solution that combines several (four, according to the product information) testosterone esters in one vial, 300 mg per ml in total. A vial holds 10 ml, so 3,000 mg. The idea is the same as classic Sustanon 250: short esters act fast while long esters hold the level.
The manufacturer does not state the exact ester ratio. For comparison, classic Sustanon 250 contains 30mg propionate, 60mg phenylpropionate, 60mg isocaproate and 100mg decanoate per ml.
This information is for research and educational purposes only. No medical advice.
Comparison
One ester or four
The same compound at the same receptor with esters of different length, as stated in the TPD lexicon. Tap a card to open its entry.
Simplified: the ester only sets how fast testosterone is released from the depot. At the receptor it is always the same testosterone. 211
How it works
All esters release the same compound: testosterone. It binds the androgen receptor and raises protein synthesis, nitrogen retention and red blood cell production. The blend is only a release trick; the active compound is always the same.
Part of the testosterone is converted to estradiol by aromatase and part to DHT. That brings the usual estrogen and androgen topics. Because short and long esters are mixed, levels rise quickly after a dose and then fall more slowly than with a short single ester.
Where it acts
Where the classic blend acted in studies
Tap a point or a card. Grey = observed in studies, all via the androgen receptor.
- Pituitary
LH fell in young men, back to baseline after stopping8
Observed in trials - Testes
Leydig cell marker INSL3 fell, recovered after stopping8
Observed in trials - Skeletal muscle
More fat-free mass, muscle thickness and strength than with training alone5
Observed in trials - Fat tissue
Total fat mass fell within 6 weeks5
Observed in trials - Bone
Spine bone density +5 percent, bone breakdown slowed6
Observed in trials - Blood
Red blood cell values shifted, more young red blood cells3
Observed in trials
Targets in the ChEMBL database15
Compound CHEMBL386630: one recorded mechanism, Agonist, direct binding (testosterone).
- Gene
- AR
- UniProt
- P10275
- ChEMBL
- CHEMBL1871
- Action
- Agonist, direct binding (testosterone)
Use and dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
Injection
The oil is ready to use and is not mixed. Intramuscular injection into the glute, thigh or shoulder is recommended; disinfect the site and rotate regularly.
- Thicker needle to draw, thinner needle to inject.
- The short ester component irritates subcutaneous fat more, so subcutaneous only in small amounts and if well tolerated.
- Mild soreness at the site during the first one to two days is common.
What the research shows
For the classic Sustanon blend there is doping control data: Forsdahl and colleagues (2015) gave volunteers a single dose of 30mg propionate, 60mg phenylpropionate, 60mg isocaproate and 100mg decanoate. All esters were detectable in blood and the detection window depended on the ester.
Weinbauer and colleagues (2003) showed in primates that at the same amount of testosterone, the release profile and aromatization shape the effects more than the total dose. For the effect of testosterone itself, Bhasin's dose-response trial (2001) is the usual reference: muscle mass and strength rose with the dose while HDL fell.
The Endocrine Society (2013) summarizes the risks of performance-level dosing. There are no controlled studies on Sustanon 300 itself.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
Protein gain in muscle per day5
Older men (65 to 75 years), 6 weeks of strength training, injection every 2 weeks, 9 participants each
Muscle protein synthesis ran at 2.13 percent per day with the blend and 1.34 percent with placebo. Breakdown rose too, but on balance clearly more protein stayed in the muscle.
Lumbar spine bone density67
Change in percent on the classic four-ester blend
Abstract values 5 and 5.0 percent. In the cortisone study bone density did not change without testosterone; in the control phase fat mass rose and lean mass fell, both reversed with testosterone.
Flagged profiles after two injections3
Share of the 9 men on the blend, randomised against placebo
Steroid profile flagged in 9 of 9, blood profile in 6 of 9 (shown as a share). The share of young red blood cells (reticulocytes) showed the use best, mainly 3 to 10 days later.
Research status
Where the research stands
There is no study on Sustanon 300 itself. Shown are registered trials with the classic four-ester blend (Sustanon 250), mostly as testosterone replacement in hormone deficiency. As of 25 Oct 2026. 14
- Preclinical Animal model (rats): testes and sperm production
- Phase 1 1 trial on components, 0 completed
- Phase 2 no registered trial
- Phase 3 1 trial on components, 1 completed
- Approval no study of this strength
Show all 13 trials on a timelineHide timeline
CDGP · NCT01797718 · 35 participants, started Oct 2013, primary endpoint reached Mar 2017. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT00355537 · 19 participants, started Feb 2006, primary endpoint reached Dec 2009.
Registry entry ↗ · Results not yet in PubMed
NCT01601327 · 119 participants, started Jan 2008, primary endpoint reached Mar 2012. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT01107067 · 32 participants, started Jun 2008, primary endpoint reached Dec 2009.
Registry entry ↗ · Results not yet in PubMed
NCT01533129 · 106 participants, started Aug 2008, primary endpoint reached Apr 2011. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT02171390 · 130 participants, started Aug 2008, primary endpoint reached Jun 2012. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT01454011 · 140 participants, started Sept 2008, primary endpoint reached Feb 2011. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT02111473 · 49 participants, started May 2009, primary endpoint reached May 2012.
Registry entry ↗ · Results not yet in PubMed
NCT01160341 · 312 participants, started Aug 2009, primary endpoint reached Jan 2010.
Registry entry ↗ · Results not yet in PubMed
NCT02111434 · 150 participants, started Jul 2013, primary endpoint reached Apr 2014.
Registry entry ↗ · Results not yet in PubMed
NCT01758094 · 25 participants, started Jan 2008, primary endpoint reached Aug 2012.
Registry entry ↗ · Results not yet in PubMed
NCT02571205 · 15 participants, started Nov 2015, primary endpoint reached Feb 2019.
Registry entry ↗ · Results not yet in PubMed
ASCEND001 · NCT07568574 · 60 participants (planned), started Mar 2026, primary endpoint planned May 2028. Tests several agents.
Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 25 Oct 2026. Phase 1: 1 trial on safety and pharmacokinetics, not shown as bars.
Side effects
Sustanon 300 carries the risk profile of every testosterone product. The higher concentration does not change that; it only means less volume per dose.
- Estrogen: water retention, rising blood pressure, gyno risk.
- Hematocrit: rises with the dose, keep an eye on the blood count.
- HPTA suppression: your own testosterone production is suppressed and the testes can shrink.
- Lipids: HDL falls.
- Androgenic: acne, hair loss if predisposed.
Practice
Testosterone, estradiol, hematocrit, lipids and liver values are usually checked before the start and during a protocol. An aromatase inhibitor is used only according to bloodwork, not by default. Sustanon blends usually contain a long ester that keeps acting for a long time, so a post-cycle plan starts only with some distance to the last dose.
- Banned in official competition (WADA S1).
Storage
Keep the oil at room temperature, in the dark and closed. Do not put it in the fridge, as the compound can crystallize in the cold. Visible crystals dissolve when the vial is warmed and swirled until the solution is clear again.